Drug IP Owner Says Boehringer's Overcharge Claim Is Capped
Licensing company Royalty Pharma has admitted that it overcharged Boehringer Ingelheim patent royalties for sales of its diabetes treatment, but argued in its lawsuit over unpaid money that anything it owed...To view the full article, register now.
Already a subscriber? Click here to view full article